Cargando…

Method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer trials: a retrospective analysis of the MRC BO06 trial in osteosarcoma

OBJECTIVES: In cancer studies, the target received dose intensity (tRDI) for any regimen, the intended dose and time for the regimen, is commonly taken as a proxy for achieved RDI (aRDI), the actual individual dose and time for the regimen. Evaluating tRDI/aRDI mismatches is crucial to assess study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lancia, Carlo, Anninga, Jakob, Spitoni, Cristian, Sydes, Matthew R., Whelan, Jeremy, Hogendoorn, Pancras C W, Gelderblom, Hans, Fiocco, Marta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549670/ https://www.ncbi.nlm.nih.gov/pubmed/31152023 http://dx.doi.org/10.1136/bmjopen-2018-022980

Ejemplares similares

A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
por: Lancia, Carlo, et al.
Publicado: (2019)

Short-term and long-term prognostic value of histological response and intensified chemotherapy in osteosarcoma: a retrospective reanalysis of the BO06 trial
por: Musta, Eni, et al.
Publicado: (2022)

Novel longitudinal Multiple Overall Toxicity (MOTox) score to quantify adverse events experienced by patients during chemotherapy treatment: a retrospective analysis of the MRC BO06 trial in osteosarcoma
por: Spreafico, Marta, et al.
Publicado: (2021)

Marginal structural models with dose-delay joint-exposure for assessing variations to chemotherapy intensity
por: Lancia, Carlo, et al.
Publicado: (2018)

Disease progression in osteosarcoma: a multistate model for the EURAMOS-1 (European and American Osteosarcoma Study) randomised clinical trial
por: Hazewinkel, Audinga-Dea, et al.
Publicado: (2022)

Intact interferon signaling in peripheral blood leukocytes of high-grade osteosarcoma patients
por: Buddingh, Emilie P., et al.
Publicado: (2012)

Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment
por: van Maldegem, Annemiek M, et al.
Publicado: (2012)

Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European Osteosarcoma Intergroup
por: McTiernan, Anne, et al.
Publicado: (2012)

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
por: Kass-Iliyya, Antoine, et al.
Publicado: (2018)

Osteosarcoma Models: From Cell Lines to Zebrafish
por: Mohseny, Alexander B., et al.
Publicado: (2012)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways
por: Cleton-Jansen, A-M, et al.
Publicado: (2009)

The value of evidence synthesis in randomised controlled trial (RCT) design, conduct and analysis: MRC clinical trials unit (CTU) at UCL experience
por: Tierney, Jayne F, et al.
Publicado: (2015)

The treatment of multiple myeloma--an important MRC trial.
por: Johnson, P. W., et al.
Publicado: (1994)

Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma
por: Strauss, Sandra J., et al.
Publicado: (2018)

Quality of Life of Patients With Osteosarcoma in the European American Osteosarcoma Study-1 (EURAMOS-1): Development and Implementation of a Questionnaire Substudy
por: Calaminus, Gabriele, et al.
Publicado: (2019)

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019)

Survival Analysis of 3 Different Age Groups and Prognostic Factors among 402 Patients with Skeletal High-Grade Osteosarcoma. Real World Data from a Single Tertiary Sarcoma Center
por: Evenhuis, Richard E., et al.
Publicado: (2021)

Patient survival after D (1) and D (2) resections for gastric cancer: long-term results of the MRC randomized surgical trial
por: Cuschieri, A, et al.
Publicado: (1999)

Accuracy and Reproducibility of Conformal Radiotherapy using Data from a Randomised Controlled Trial of Conformal Radiotherapy in Prostate Cancer (MRC RT01, ISRCTN47772397)
por: Stanley, S., et al.
Publicado: (2008)

Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
por: Smeland, Sigbjørn, et al.
Publicado: (2019)

Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells
por: Buddingh, Emilie P., et al.
Publicado: (2011)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
por: Short, J. M., et al.
Publicado: (2023)

Consumer involvement at the MRC Clinical Trials Unit: results of a survey
por: Vale, Claire L, et al.
Publicado: (2011)

Toxicity of culture material of Fusarium verticillioides strain MRC 826 to nonhuman primates.
por: Gelderblom, W C, et al.
Publicado: (2001)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

A simulated sequential analysis based on data from two MRC trials.
por: Donaldson, A. N., et al.
Publicado: (1993)

P_t dependence and Bo <--> Bo bar mixing
por: Prulhière, F
Publicado: (1992)

Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo
por: Meijer, Danielle, et al.
Publicado: (2011)

Paratesticular desmoplastic small round cell tumour: an unusual tumour with an unusual fusion; cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH
por: Cliteur, Vincent PM, et al.
Publicado: (2012)

MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma
por: Sarver, Aaron L, et al.
Publicado: (2013)

MRC2014: Extensions to the MRC format header for electron cryo-microscopy and tomography
por: Cheng, Anchi, et al.
Publicado: (2015)

Historical Perspectives of the Role of the MRC
por: Williams, P. O.
Publicado: (1990)

Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)
por: Barnes, David J., et al.
Publicado: (2022)

When participants get involved: reconsidering patient and public involvement in clinical trials at the MRC Clinical Trials Unit at UCL
por: Vale, Claire L., et al.
Publicado: (2018)

Modelling Trial-by-Trial Changes in the Mismatch Negativity
por: Lieder, Falk, et al.
Publicado: (2013)

Clinical trial size - the perfect, the practicable and the present: MRC/CRC meeting, 26 March 1987
Publicado: (1988)

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience
por: Adams, R A, et al.
Publicado: (2009)

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_sbmh8mc9vs1pk9d1pmgqv94he4